Zika is a viral infection generally spread by mosquitos. Zika virus can also spread through sex with an infected person or from a pregnant woman to her baby. A Zika virus test looks for signs of the infection in urine or blood. Mosquitos that carry the Zika virus are most common in areas of the world with tropical climates. These include islands in the Caribbean and the Pacific, Central America, some parts of Africa, South America, and Mexico. Mosquitos carrying the Zika virus have also been found in parts of the United States, including South Florida. A Zika virus test is used to find out whether the person has been infected with Zika infection. The test is usually applied on pregnant women who have recently traveled to an area where there is a risk of Zika infection.According to AMA, the market for Zika Virus Testing is expected to register a CAGR of 5.5% during the forecast period to 2024. This growth is primarily driven by Increasing Prevalence of Zika Virus Infection, Government Initiatives to Develop Innovative Tests, Increasing R&D by Biopharmaceutical Companies and Technological Advancements in Medical Diagnostics.
The Diseases & Therapeutic Areas sector in the North America region has been increasing at a strong rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Abbott (United States), Altona Diagnostics GmbH (Germany), Chembio Diagnostic Systems Inc. (United States), ELITechGroup (France), F. Hoffmann-La Roche Ltd (Switzerland), Fast Track Diagnostics Ltd (Luxembourg), Genekam (Germany), Luminex Corporation (United States), Primerdesign Ltd (United Kingdom) and Quest Diagnostics (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
On 6 Oct 2017, FDA has approved Roche cobas Zika as first commercially-available donor screening test for Zika virus. and On 2 Feb. 2017 Abbott has announced that the U.S. Food and Drug Administration (FDA) has authorized its molecular test, the Abbott RealTime ZIKA test, to detect Zika virus in whole blood for emergency use. It is the preliminary molecular test completed by a commercial manufacturer official to detect Zika in whole blood samples, which is significant since recent research suggests Zika virus can be detected in whole blood for a longer period of time and at higher levels versus testing with serum and urine sample types.
- Increasing Prevalence of Zika Virus Infection
- Government Initiatives to Develop Innovative Tests
- Increasing R&D by Biopharmaceutical Companies
- Technological Advancements in Medical Diagnostics
- High Costs of Testing Kits
- Sluggish Adoption of New Technologies in the Emerging Markets
OpportunitiesRising Adoption of New Technologies in the Medical Device Sector
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization of the Report:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase